Close

pSBCAR1 CD20 (1F5) h(28ζ) (CAR-SB-LX0074)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CD20 (1F5) h(28ζ), which is constructed for the engineering of T cells to target human CD20. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CD20 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia (ALL).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Acute lymphoblastic leukemia (ALL)
  • Generation
  • Second
  • Vector Name
  • pSBCAR1
  • Vector Length
  • ~6kb
  • Vector Type
  • Sleeping Beauty (SB) transposon
  • Receptor Construction
  • scFv-CD28-CD3ζ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 1F5
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data Cyt

Fig.1 Transduced T cells exhibit CD20-specific cytolytic activity in vitro.

CAR Construction : 1F5-CD28-41BB-CD3ζ Latest CAR Construction

Fig.1 Transduced T cells exhibit CD20-specific cytolytic activity in vitro.

iC9-CD20CAR-Δ19 T cells transduced with CD20-CAR (CD20-CAR T), or non-transduced (mock) T cells were co-cultured with EL4, Daudi, and Granta in various effector to target (E:T) ratios.

Budde L E, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J]. PloS one, 2013, 8(12): e82742.

Complete CAR data FCM

Fig.2 Anti-tumor effect of the transduced T cells.

CAR Construction : 1F5-CD28-41BB-CD3ζ Latest CAR Construction

Fig.2 Anti-tumor effect of the transduced T cells.

Mock or iC9-CD20CAR-Δ19 transduced T cells were co-cultured with CD20+ Ramos cells in various Effector to Target ratios (E:T) for 48 hours. Cells were then stained with antibodies recognizing CD22 and CD3. Flow cytometric analysis was used to determine the presence of Ramos cells (CD22+CD3-) and T cells (CD22-CD3+).

Budde L E, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J]. PloS one, 2013, 8(12): e82743.

Complete CAR data ELISA

Fig.3 Cytokine production.

CAR Construction : 1F5-CD28-41BB-CD3ζ Latest CAR Construction

Fig.3 Cytokine production.

Expanded T cells secreted IL2, IFN-γ and TNF-α after co-culture with CD20-expressing Ramos target cells for 48 hours.

Budde L E, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J]. PloS one, 2013, 8(12): e82744.

Complete CAR data BI

Fig.4  Anti-tumor activity of transduced T cells in vivo.

CAR Construction : 1F5-CD28-41BB-CD3ζ Latest CAR Construction

Fig.4 Anti-tumor activity of transduced T cells in vivo.

Eradication of CD20+ Raji tumors in NOD-SCID mice by CD20-CAR T cells but not non-transduced T cells (Mock T) as measured by in vivo bioluminescent imaging.

Budde L E, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J]. PloS one, 2013, 8(12): e82745.

Complete CAR data FuncS

Fig.5  Anti-tumor activity of transduced T cells in vivo.

CAR Construction : 1F5-CD28-41BB-CD3ζ Latest CAR Construction

Fig.5 Anti-tumor activity of transduced T cells in vivo.

Kaplan-Meier survival curves of mice receiving iC9-CD20CAR-Δ19 T treatment (CD20-CAR T) or non-transduced mock T cell treatment (NT).

Budde L E, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma[J]. PloS one, 2013, 8(12): e82746.

CAR scFv data IF

Fig.6  CD20 binding assay.

CAR Construction : Latest CAR Construction

Fig.6 CD20 binding assay.

Binding of 1F5-IgG1 or 1F5-IgA2 and respective control antibodies to human CD20 transfected CHO-K1 cells was analysed by indirect immunofluorescence using a fluorescein isothicyanate (FITC)-labelled human jlight chain antibody.

Lohse S, Loew S, Kretschmer A, et al. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity[J]. British journal of haematology, 2018, 181(3): 413-417.

CAR scFv data ELISA

Fig.7  Binding activity of 1F5 scFv-Ig compared with 1F5.

CAR Construction : Latest CAR Construction

Fig.7 Binding activity of 1F5 scFv-Ig compared with 1F5.

A total of 10^5 Ramos cells were incubated with various concentrations of 1F5 scFv-Ig (GS1) or 1F5, followed by incubation with a peroxidase-conjugated GAH or GAM secondary Ab.

Shan, D., Press, O. W., Tsu, T. T., Hayden, M. S., & Ledbetter, J. A. (1999). Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. The Journal of Immunology, 162(11), 6589-6595.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 (1F5) h(CD28-CD3ζ) CAR, pSBCAR1 (CAR-SB-LX0074). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.